Nathan Wong, PhD, FACC, FAHA, FNLA, is the director of the University of California (UC) Irvine Heart Disease Prevention Program as well as a professor at UC Irvine School of Medicine's Department of Internal Medicine.
Lp(a) Levels: A Continuous Relationship With ASCVD Levels and Consistent Throughout a Lifetime
March 31st 2025Experts discuss the evidence supporting the continuous relationship between lipoprotein(a) (Lp[a]) levels and atherosclerotic cardiovascular disease (ASCVD), as recognized by the National Lipid Association, and explore how Lp(a) levels may change throughout a person’s lifetime or in response to lifestyle factors.
Studying the Association Between Elevated Lp(a) Levels and Risk of Atherosclerotic Disease
March 31st 2025Experts discuss the relationship between lipoprotein(a) (Lp[a]) levels and atherosclerotic cardiovascular disease (ASCVD) risk, with findings from a large US population study, and explore how these findings could impact clinical practice and the management of patients at risk for ASCVD.
The Role of Prevention in the Management of Atherosclerotic Disease and Aortic Stenosis
March 24th 2025Experts discuss the clinical and economic burden of atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis in the US, exploring their impact on health care systems, the importance of prevention in reducing this burden, and the challenges of implementing preventive strategies, while considering the potential benefits of improved risk assessment and prevention in the ASCVD space.
Introduction and Burden of Atherosclerotic Disease and Aortic Stenosis
March 24th 2025Experts discuss atherosclerotic cardiovascular disease and aortic stenosis, as well as their burden, highlighting their prevalence, impact on patient health, and the growing need for effective management strategies.